Begin main content

Natriuretic Peptide Testing for Cardiac Amyloidosis: Clinical Effectiveness, Cost-Effectiveness and Guidelines

Last updated: August 14, 2019
Project Number: RB1365-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical utility of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis?
  2. What is the cost-effectiveness of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis?
  3. What are the evidence-based guidelines for natriuretic peptide testing for monitoring of light chain cardiac amyloidosis?

Key Message

Three non-randomized studies were identified regarding the clinical utility of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis. In addition, two evidence-based guidelines were identified regarding natriuretic peptide testing for monitoring of light chain cardiac amyloidosis. No economic evaluations were identified regarding the cost-effectiveness of natriuretic peptide testing for diagnosis and prognosis of light chain cardiac amyloidosis